LHI0.F Algorae Pharmaceuticals Limited

Healthcare Biotechnology Frankfurt Exchange
0.0035 EUR
Close of Nov 12, 2026
0.0030 0.0160
Market cap
EUR 7.10M
P/E
-
P/B
2.31x
ROE
-63.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is LHI0.F undervalued?

Graham number

The Graham number of Algorae Pharmaceuticals Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Algorae Pharmaceuticals Limited fundamental analysis

No fundamental analysis for Algorae Pharmaceuticals Limited yet.

Algorae Pharmaceuticals Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Algorae Pharmaceuticals Limited

Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingr…

Full company profile